Cargando…
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recen...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080691/ https://www.ncbi.nlm.nih.gov/pubmed/27782862 http://dx.doi.org/10.1186/s13073-016-0365-1 |